How Innate Pharma uses Causaly for systematic target identification
How Innate Pharma uses Causaly for systematic target identification
Challenges
From weeks to hours: Streamlining Target Evaluation to enable confident, data-led strategy
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As part of their R&D operations, Innate is heavily focused on identifying novel tumor antigens and evaluating their potential as therapeutic targets. Their research relies heavily on rapid and reliable access to literature and clinical data.
Florent Carrette leads the science of early preclinical and clinical-stage projects aiming at developing new antibody-based therapies for cancer patients. He and his team conduct extensive evaluations to identify promising targets for therapeutic development. Causaly has become an essential part of this process, helping them review the biomedical landscape with speed and scientific precision.
The Challenge with traditional search methods
Prior to adopting Causaly, identifying and evaluating tumor antigens required significant manual effort to review and identify documents of interest with the traditional search methods. Literature searches were time-consuming, exploration depth depended on people’s backgrounds and experiences, and compiling insights into actionable summaries meant stitching together multiple sources. This labor-intensive process limited both efficiency and scope.
How Causaly Helped
How Causaly transformed target identification and validation
Causaly has transformed Florent Carrette’s tumor antigen selection and validation process for targets with therapeutic potential. Thanks to the quick retrieval of documents and the transparent results, it has accelerated the decision-making process and improved his confidence in the findings.
Causaly allowed Florent to extract insights from multiple studies and efficiently map and compare antigen expression profiles across different cancers.
His analysis revealed untapped tumor types for targeting; opportunities that would have remained hidden without Causaly.
Strategically evaluating targets
Florent's workflow begins with target identification, followed by the validation of the prioritized targets by evaluating their expression patterns and druggability. In this case, he wanted to focus specifically on altered antigen expression profiles in tumor tissues, with no presence in healthy cells. He assessed binding properties, such as ligand-receptor interactions, to help him uncover therapeutic angles by developing antibodies with the appropriate properties.
Causaly helped surface untapped opportunities
When tasked with profiling tumor antigen expression across diverse tumor types, Causaly was the best-suited platform to tackle the complexity of the challenge. It allowed Florent to extract insights from multiple studies and map competitive activity with precision. This analysis revealed untapped tumor types for targeting; opportunities that would have remained hidden without Causaly.
He notes: “The selection of tumor antigens was greatly facilitated by Causaly, improving the decision-making process.”
[The Delta analysis view was used for the holistic view of tumor antigens in different cancer subtypes of interest. (A, B, C were used for different cancer stages.]
Causaly in-house scientists were instrumental in generating high-impact findings
Causaly’s team of in-house scientists supported the target selection process, by using our interactive knowledge graphs to show a comprehensive antigen list, as well as the incorporation of quality filters that would facilitate target identification.
While Florent continues to explore ways to assess intra-tumor heterogeneity, such as integrating immunohistochemistry or single-cell RNA-seq, Causaly has already laid the foundation for more informed decision making.
“Causaly is my new friend; I use it every day. Every time I have a question it’s my companion.”
More case studies
.png)
Get to know Causaly
What would you ask the team behind life sciences’ most advanced AI? Request a demo and get to know Causaly.
Request a demo